$15.59
Tandem Diabetes Care
Performance
Dividends
-58.42%
1W
1M
YTD
1Y
3Y
10/36
Growth Score
9/36
Dividend Score
Valuation
PE Ratio
-5.63
PS Ratio
0.94
RSI
-
0
PEG Ratio
-0.04
2
PRG Ratio
0.53
PDG Ratio
0
Growth
0-7%126%011%011%
-135%57%11%52%
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule of 40
57.16%
1
Gross Margin
46.57%
2
Current Ratio
2.3
Return on Assets
-19.94%
Return on Equity
-82.64%
Return on inv. Capital
-27.86%
Institutional Holder
86.028.452089.195.713
2691317
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 940.20M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 -96.03M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 489.57M
2018
2019
2020
2021
2022
2023
2024
6
Events
TNDM
Tandem Diabetes Care
in 260 days
after market close
Earnings per Share is expected with - and revenue with - .
TNDM
Tandem Diabetes Care
in 197 days
after market close
Earnings per Share is expected with - and revenue with - .
TNDM
Tandem Diabetes Care
in 85 days
after market close
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Medical - Devices
IPO Date
14.11.2013
MaketCap
1.04B
Country
US
CEO
John F. Sheridan
Description
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Updated 14.07.2025